Good morning. Elizabeth Cooney here writing from STAT’s Boston HQ, where we’re bracing for the heat wave that’s about to cook our edge of the East Coast. Ed Silverman is no doubt dreaming of weekend plans in between gathering intel in our nation’s capital. He’ll be back on the Pharmalot campus next week. Before I go, here’s a bookmark suggestion for you: STAT’s Drug Pricing Policy Tracker, a living list of developments curated by our Washington correspondents Nicholas Florko and Lev Facher. Enjoy.

Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply or raise costs for its own citizens, officials have told U.S. authorities, according to documents obtained by Reuters. That could be a new setback for the Trump administration and its efforts to tackle high drug prices, as well as for U.S. lawmakers who have argued they can lower skyrocketing prescription drug prices by approving lower-priced imports from Canada. At least 10 U.S. states have passed or proposed laws to allow such imports, but actual shipments require federal approval to be legal.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Concerning the Vanda item, instead of too little clinical data, it seems one company is offering “a boatload?”

Your daily dose of news in health and medicine

Privacy Policy